Report overview
The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.
This report aims to provide a comprehensive presentation of the global market for Cancer Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Monoclonal Antibodies. This report contains market size and forecasts of Cancer Monoclonal Antibodies in global, including the following market information:
Global Cancer Monoclonal Antibodies Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global Cancer Monoclonal Antibodies Market Sales, 2018-2023, 2024-2032, (K Units)
Global top five Cancer Monoclonal Antibodies companies in 2022 (%)
The global Cancer Monoclonal Antibodies market was valued at US$ 35310 million in 2022 and is projected to reach US$ 63580 million by 2029, at a CAGR of 8.8% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cancer Monoclonal Antibodies manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cancer Monoclonal Antibodies Market, by Type, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Cancer Monoclonal Antibodies Market Segment Percentages, by Type, 2022 (%)
Murine Antibodies
Chimeric and Humanised Antibodies
Fully Humanized Antibodies
Others
Global Cancer Monoclonal Antibodies Market, by Application, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Cancer Monoclonal Antibodies Market Segment Percentages, by Application, 2022 (%)
Liver
Breast
Blood
Brain
Hodgkins and Non-Hodgkins lymphoma
Colorectal
Leukaemia
Others
Global Cancer Monoclonal Antibodies Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Cancer Monoclonal Antibodies Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cancer Monoclonal Antibodies revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Cancer Monoclonal Antibodies revenues share in global market, 2022 (%)
Key companies Cancer Monoclonal Antibodies sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Cancer Monoclonal Antibodies sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
F. Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Takeda Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cancer Monoclonal Antibodies, market overview.
Chapter 2: Global Cancer Monoclonal Antibodies market size in revenue and volume.
Chapter 3: Detailed analysis of Cancer Monoclonal Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cancer Monoclonal Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Cancer Monoclonal Antibodies capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
